Innovent starts China's first trial of a novel cancer immunotherapy - STAT

Innovent starts China's first trial of a novel cancer immunotherapy - STAT

More reads

• Innovent starts China’s first trial of a novel cancer immunotherapy. (STAT Plus)
• It’s time to bring generic drug manufacturing back to the U.S. (STAT)
• Lawmakers, government watchdog blast FDA for poor oversight of U.S. drug supply chain. (STAT Plus)
• Biotech’s smart money is already focused on disease prevention, boosting immune systems and longevity. (MarketWatch)